Biology Reference
In-Depth Information
O'Shaughnessy MJ, Chen ZM, Gramaglia I, Taylor PA, Panoskaltsis-Mortari A, Vogtenhuber C,
Palmer E, Grader-Beck T, Boussiotis VA, Blazar BR (2007) Elevation of intracellular cyclic
AMP in alloreactive CD4(+) T Cells induces alloantigen-specific tolerance that can prevent
GVHD lethality in vivo. Biol Blood Marrow Transplant 13:530-542
Ohta K, Fukuchi Y, Grouse L, Mizutani R, Rabe KF, Rennard SI, Zhong NS (2004) A prospective
clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respir Med
98:1016-1024
Papakostantinou E, Xenos K, Markantonis SL, Druska S, Stratigos A, Katsambas A (2005)
Efficacy of 2 weeks' application of theophylline ointment in psoriasis vulgaris. J Dermatol
Treat 16:169-170
Parkkonen J, Hasala H, Moilanen E, Giembycz MA, Kankaanranta H (2007) Phosphodiesterase 4
inhibitors delay human eosinophil and neutrophil apoptosis in the absence and presence of
salbutamol. Pulm Pharmacol Ther 21:499-506
Perez-Torres S, Miro X, Palacios JM, Cortes R, Puigdomenech P, Mengod G (2000) Phosphodi-
esterase type 4 isozymes expression in human brain examined by in situ hybridization
histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat
brain. J Chem Neuroanat 20:349-374
Peter D, Jin SL, Conti M, Hatzelmann A, Zitt C (2007) Differential expression and function of
phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of
PDE4D. J Immunol 178:4820-4831
Phillips P, Bennetts M, Banner K, Ward J, Wessels D, Fuhr R (2007) The PDE4 inhibitor UK-
500,001 does not significantly inhibit airway responses to allergen and histamine. Eur Resp J:
490s. Ref Type: Abstract
Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD (2005) Roflumilast -
an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised
controlled trial. Lancet 366:563-571
Rennard SI (2004) Treatment of stable chronic obstructive pulmonary disease. Lancet 364:791-802
Rennard SI, Schachter N, Strek M, Rickard K, Amit O (2006) Cilomilast for COPD: results of a 6-
month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest
129:56-66
Robichaud A, Tattersall FD, Choudhury I, Rodger IW (1999) Emesis induced by inhibitors of type
IV cyclic nucleotide phosphodiesterase (PDE IV)
in the ferret. Neuropharmacology
38:289-297
Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC (2001) PDE4 inhibitors induce
emesis in ferrets via a noradrenergic pathway. Neuropharmacology 40:262-269
Robichaud A, Savoie C, Stamatiou PB, Lachance N, Jolicoeur P, Rasori R, Chan CC (2002a)
Assessing the emetic potential of PDE4 inhibitors in rats. Br J Pharmacol 135:113-118
Robichaud A, Stamatiou PB, Jin SL, Lachance N, Macdonald D, Laliberte F, Liu S, Huang Z,
Conti M, Chan CC (2002b) Deletion of phosphodiesterase 4D in mice shortens alpha(2)-
adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 110:
1045-1052
Roth BL, Sheffler DJ, Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-
selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359
Salvi SS, Barnes PJ (2009) Chronic obstructive pulmonary disease in non-smokers. Lancet
374:733-743
Sanz MJ, Cortijo J, Taha MA, Cerda-Nicolas M, Schatton E, Burgbacher B, Klar J, Tenor H,
Schudt C, Issekutz AC, Hatzelmann A, Morcillo EJ (2007) Roflumilast inhibits leukocyte-
endothelial cell interactions, expression of adhesion molecules and microvascular permeability.
Br J Pharmacol 152:481-492
Schafer P, Parton A, Gandhi A, Capone L, Adams M, Wu L, Bartlett J, Loveland M, Gilhar A,
Cheung YF, Baillie G, Houslay M, Man HW, Muller G, Stirling D (2010) Apremilast, a cAMP
phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model
of psoriasis. Br J Pharmacol 159:842-855
